Breast cancer;
Triple negative;
Survival outcome;
CHEMOTHERAPY;
PROGNOSIS;
IMPACT;
D O I:
10.1007/s40944-024-00909-7
中图分类号:
R71 [妇产科学];
学科分类号:
100211 ;
摘要:
BackgroundBreast cancer is the second most frequent cancer among both sexes worldwide cancer. Triple-negative breast cancer (TNBC) is associated with high recurrence rate and metastasis, which significantly shorten survival after the first metastatic event. This study has been conducted to determine the prognostic significance of TNBC and explore its correlation tumor grade pathologic stage and survival outcome.Materials and MethodsThis was a non-interventional observational, retrospective and prospective cohort study of 140 histologically confirmed breast cancer cases treated at our institute (70 cases each of TNBC and non-TNBC as study and control groups, respectively). The blocks and slides were retrieved and reviewed from 2016-2019. The study period was from January 2020 to September 2023. The data on patient's clinical details, histopathological diagnosis, treatment and follow-up were retrieved from hospital information system and pathology records. Disease-free survival and overall survival of each category were analyzed by the Kaplan-Meier method.ResultsTNBC was accounted for 20.21% cases. The statistically significant clinicopathological parameters affecting survival status of TNBC and non-TNBC patients were age (p = 0.0001), tumor size (p = 0.032), lymph node metastasis (p = 0.002), and stage (p = 0.010). A significant correlation was noticed with treatment compliance and survival outcome within the cases and controls (p = 0.005 and 0.01, respectively).ConclusionTNBC is aggressive tumor associated with a higher risk of recurrence, distant metastasis and poor survival outcome. TNBC is difficult to treat due to lack of established predictive biomarkers and targeted therapy.
机构:
Inst Alexander Fleming, Dept Oncol, ANZ, RA-1426 Buenos Aires, DF, ArgentinaInst Alexander Fleming, Dept Oncol, ANZ, RA-1426 Buenos Aires, DF, Argentina
Chacon, Reinaldo D.
Costanzo, Maria V.
论文数: 0引用数: 0
h-index: 0
机构:
Inst Alexander Fleming, Dept Oncol, ANZ, RA-1426 Buenos Aires, DF, ArgentinaInst Alexander Fleming, Dept Oncol, ANZ, RA-1426 Buenos Aires, DF, Argentina
机构:
Clinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, 1090 Vienna
Department of Medicine 1 (Haematology and Medical Oncology), Academic Teaching Hospital Elisabethinen, LinzClinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, 1090 Vienna
Bartsch R.
Ziebermayr R.
论文数: 0引用数: 0
h-index: 0
机构:
Department of Medicine 1 (Haematology and Medical Oncology), Academic Teaching Hospital Elisabethinen, LinzClinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, 1090 Vienna
Ziebermayr R.
Zielinski C.C.
论文数: 0引用数: 0
h-index: 0
机构:
Clinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, 1090 ViennaClinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, 1090 Vienna
Zielinski C.C.
Steger G.G.
论文数: 0引用数: 0
h-index: 0
机构:
Clinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, 1090 ViennaClinical Division of Oncology, Department of Medicine 1 and Cancer Centre, Medical University of Vienna, 1090 Vienna